Pure Global

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab - Trial NCT06304545

Access comprehensive clinical trial information for NCT06304545 through Pure Global AI's free database. This Phase 2 trial is sponsored by Harbin Medical University and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06304545
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06304545
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
Long-course Concurrent Chemoradiotherapy Combined With Camrelizumab in the Neoadjuvant Treatment of Locally Advanced/Low Anus-preserving Rectal Cancer: a Phase II Single-arm Study.

Study Focus

Rectal Cancer

Camrelizumab

Interventional

drug

Sponsor & Location

Harbin Medical University

Timeline & Enrollment

Phase 2

Mar 15, 2024

Mar 15, 2027

48 participants

Primary Outcome

Pathological Complete Response rate

Summary

This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of
 long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in
 the treatment of locally advanced/low rectal cancer requiring anus preservation.

ICD-10 Classifications

Malignant neoplasm of rectum
Carcinoma in situ: Rectum
Benign neoplasm: Rectum
Secondary malignant neoplasm of large intestine and rectum
Carcinoma in situ: Rectosigmoid junction

Data Source

ClinicalTrials.gov

NCT06304545

Non-Device Trial